

Parent Information – Pharmacy Department

Change from Strattera capsules to generic atomoxetine capsules

Introduction

The purpose of this leaflet is to explain the change from using a brand of atomoxetine capsules called Strattera, to a generic brand named Atomoxetine. GPs are also going to be switching some of their patients to this new brand of atomoxetine capsules.

What is changing?

Your child has currently been taking the Strattera brand of capsules and is now to be prescribed generic atomoxetine capsules instead.

Strattera capsules and generic atomoxetine capsules have the same type of medicine in them called atomoxetine which is prescribed for treating Attention Deficit Hyperactivity Disorder (ADHD). These capsules have different brand names as they are made by different companies.

The capsules are taken as a single daily dose but can be taken twice daily, i.e. in the morning and late afternoon or early evening. The beneficial effects of the generic atomoxetine capsules will therefore be the same as when your child was taking the Strattera capsules.

Why is this change happening?

This change is happening because generic atomoxetine capsules are less expensive than Strattera capsules. By using generic atomoxetine capsules, the money freed up can be invested into other NHS services while the treatment of ADHD will be just as good.

What do I have to do?

You do not need to do anything. The prescription for the new generic atomoxetine capsules will continue to be prescribed by your child's doctor or nurse as before. You will be able to get the prescription dispensed in the outpatient hospital pharmacy at the Lister or New QEII hospital. The medication is taken at exactly the same time of day as before.

What are the benefits for my child?

There are no additional benefits. However, as mentioned above, the money freed up would be used for other NHS services; this will be a benefit for everyone who uses the NHS.

What if I am unhappy with the change?

Please contact your child's ADHD specialist doctor or nurse to discuss your concerns, they will be happy to discuss them with you. For contact details, please visit our website - www.addmore.org.uk

Date of publication: December 2019

Authors: L. Summers, Lead Paediatric Pharmacist

www.enherts-tr.nhs.uk

Dr S. Ozer and Dr V. Tyagi Review Date: December 2022 Version: 01 © East and North Hertfordshire NHS Trust

